6 June 2024
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine" or the "Company")
Notice of AGM and
Directorate Change
Ondine Biomedical Inc. (AIM: OBI)
announces that the notice of the Company's 2024 Annual General
Meeting ("AGM") and the associated form of proxy have been
published today on the Company's website at https://ondinebio.com/investors/reports-documentation/.
Printed copies of the notice of AGM
and form of proxy will be posted today to registered shareholders
who have elected to receive paper communications.
The Company's AGM will be held
virtually at 16:00 BST (08:00 Pacific time) on 28 June 2024.
Details of how to access the meeting are contained in the notice of
AGM.
All shareholders are encouraged to
submit their vote by proxy, well in advance of the meeting. Details
of how to vote by proxy are contained in the notice of AGM. All
valid proxy votes (whether submitted electronically or in hard copy
form) will be included in the poll vote to be taken at the
meeting.
The items of business to be voted on at the Meeting
are:
· the
re-election of Carolyn Cross, Nicolas G. Loebel, Jean Charest, Jean
Duvall, Junaid Bajwa, Michael Farrar, and Craig Tooman as directors
of the Company to hold office until the 2025 annual meeting of
shareholders or until their successors are elected and qualified,
subject to earlier resignation or removal. Non-Independent Director
Dr. Simon Sinclair is not standing for re-election to the Board in
order to focus on his role as Ondine's Chief Medical Officer,
leading the Company's Phase 3 clinical trial efforts. Dr. Sinclair
will continue to serve as a Director until the AGM;
· the
re-appointment of PricewaterhouseCoopers LLP, Chartered
Professional Accountants, as auditors for the Company for the
ensuing year; and
· to
transact such other business as may properly come before the
Meeting.
The result of the AGM will be
announced after its conclusion and published on the Company's
website.
A separate release will be made
relating to the announcement of Ondine's full year results to 31
December 2023 and the expected publication of the Company's Annual
Report and Accounts.
**ENDS**
|
Ondine Biomedical
Inc.
|
|
|
Angelika Vance, Corporate
Communications
|
+001 (604) 838 2702
|
|
|
|
|
Singer Capital Markets (Nominated Adviser and Joint
Broker)
|
|
|
Aubrey Powell, Sam
Butcher
|
+44 (0)20 7496 3000
|
|
|
|
|
RBC
Capital Markets (Joint Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical
Inc.
Ondine Biomedical Inc. is a clinical Canadian life
sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark
in Europe and the UK and is approved in Canada and several other
countries under the name Steriwave®. In the US, it has been granted
Qualified Infectious Disease Product designation and Fast Track
status by the FDA and is currently undergoing clinical trials for
regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.